Thyme Care

Thyme Care announced $125M+ in Series E financing on September 2, 2026. Thyme Care raised more than $125 million in a Series E led by Morgan Health at a valuation of more than $2 billion and established Thyme Companies to build new oncology businesses.

Round details

The financing includes backing from Morgan Health, Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures. The company reported a $2B+ valuation alongside the transaction.

• Round: Series E
• Capital announced: $125M+

How the company plans to use the capital

Thyme Care said the new capital will accelerate its growth and establish Thyme Companies, a parent entity building a portfolio of new oncology businesses. Areas under active development include lower-cost biosimilar adoption and clinical trial accrual.

Why this matters for GTM teams

Morgan Health led the round, with Humana and CVS Health Ventures among the participating investors, and the company said Thyme Companies will build a broader portfolio of businesses addressing distinct parts of the oncology journey.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Thyme Care Series E announcement.